🔗 Share this article The Global Health Body Raises Concern Over Severe Scarcity of Weight-Loss Injections Under 10% of people that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the WHO as it publishes its inaugural advice on the therapies. Considering over a billion people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments. Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to widespread availability to the treatments that can help people shift significant weight, explains the body. Weight-Loss Drug Scarcity Even in the present most favorable outlook, the supply of GLP-1 therapies might only reach around 100 million people – less than 10% of eligible patients, per the health organization. The recommendation encourages nations and manufacturers to widen availability, via measures including voluntary licensing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Jabs Operate The injections mimick a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so users reduce food intake. Individuals usually see weight reduction in the initial weeks of beginning the weekly injections. Research indicates people may regain a significant portion after a year of halting the medication, because their usual hunger resume. Being overweight or obese increases your chance for contracting health problems, like diabetes, heart disease, brain attack, and specific malignancies. Excess weight impacts people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.
Under 10% of people that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the WHO as it publishes its inaugural advice on the therapies. Considering over a billion people worldwide now classified as obese, it is urging more widespread and fairer availability to these injectable treatments. Per estimates, in excess of 2,000,000,000 are projected to be living with obesity by 2030 unless action is taken. "The new guidelines recognises that obesity is a long-term condition that can be managed with thorough and ongoing support," remarked the agency's head Tedros Adhanom Ghebreyesus. Significant expense, constrained manufacturing, and distribution challenges are significant obstacles to widespread availability to the treatments that can help people shift significant weight, explains the body. Weight-Loss Drug Scarcity Even in the present most favorable outlook, the supply of GLP-1 therapies might only reach around 100 million people – less than 10% of eligible patients, per the health organization. The recommendation encourages nations and manufacturers to widen availability, via measures including voluntary licensing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in several nations in 2026. The Way Weight-Loss Jabs Operate The injections mimick a natural hormone to slow digestion, reduce hunger and increase feelings of fullness so users reduce food intake. Individuals usually see weight reduction in the initial weeks of beginning the weekly injections. Research indicates people may regain a significant portion after a year of halting the medication, because their usual hunger resume. Being overweight or obese increases your chance for contracting health problems, like diabetes, heart disease, brain attack, and specific malignancies. Excess weight impacts people in countries worldwide and was associated with 3.7 million fatalities worldwide in 2024, per the health agency.